Diagnoses and Treatments of Metastatic Endometrial Cancer

Dear Colleagues,

Uterine cancer stands as the most prevalent gynecologic malignancy in developed nations, presenting a significant health challenge and, despite advancements, its mortality rate continues to escalate, underscoring the urgency of further research and innovative therapeutic strategies. Contributing factors to this rising incidence are multifaceted, including hormonal imbalances, prolonged menstruation, nulliparity, advancing age, obesity, hormone therapy for breast cancer, and hereditary syndromes predisposing individuals to cancer. Of particular concern are advanced-stage or endometrial cancers with extrauterine metastasis, compounded by suboptimal therapeutic options in current clinical practice. Hence, the forthcoming issue of the journal Cancers endeavors to address this pressing concern by soliciting submissions focusing on endometrial cancer diagnosis (both pathological and imaging modalities) and management.

We invite contributions encompassing research or reviews that enhance our understanding of endometrial cancer metastasis and improve patient survival rates. Topics of interest include, but are not limited to, investigations into FIGO 2023 staging-related issues, such as the correlation of aggressive histologic types with cancer metastasis; cases of histologically low-grade endometrial cancer with recurrence or metastasis; synchronous endometrial and ovarian cancers; lymphovascular space invasion (LVSI) quantification in hysterectomy specimens; molecular classification of endometrial cancer; management strategies for POLE mutant endometrial cancers; genetic syndromes associated with endometrial cancers; targeted therapies; and immunotherapies for advanced endometrial cancers, along with the outcomes of relevant clinical trials.

In conclusion, this Special Issue aims to foster a comprehensive understanding of metastatic endometrial cancer—from diagnosis to therapy—and to provide a platform for disseminating cutting-edge research that promises to advance clinical practice and improve patient outcomes.

Prof. Dr. Wenxin Zheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• endometrial cancer
• mesonephric-like adenocarcinoma
• pilomatrix-like high-grade endometrioid carcinomas
• endometrial carcinosarcomas showing different prognosis based on different epithelial and mesenchymal components
• pathologic diagnosis
• imaging studies
• target therapy
• clinical trials